SsAAVs Containing Cassettes Encoding SaCas9 and Guides Targeting Hepatitis B Virus Inactivate Replication of the Virus in Cultured Cells

Overview

Journal Sci Rep

Specialty Science

Date 2017 Aug 9

PMID 28785016

Citations 38

Authors

Tristan Scott

Buhle Moyo

Samantha Nicholson

Mohube Betty Maepa

Koichi Watashi

Abdullah Ely

Marc S Weinberg

Patrick Arbuthnot

Affiliations

Soon will be listed here.

Abstract

Management of infection with hepatitis B virus (HBV) remains a global health problem. Persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is responsible for modest curative efficacy of currently licensed drugs. Novel gene editing technologies, such as those based on CRISPR/Cas9, provide the means for permanently disabling cccDNA. However, efficient delivery of antiviral sequences to infected hepatocytes is challenging. A limiting factor is the large size of sequences encoding Cas9 from Streptococcus pyogenes, and resultant incompatibility with the popular single stranded adeno-associated viral vectors (ssAAVs). We thus explored the utility of ssAAVs for delivery of engineered CRISPR/Cas9 of Staphylococcus aureus (Sa), which is encoded by shorter DNA sequences. Short guide RNAs (sgRNAs) were designed with cognates in the S open reading frame of HBV and incorporated into AAVs that also encoded SaCas9. Intended targeted mutation of HBV DNA was observed after transduction of cells with the all-in-one vectors. Efficacy against HBV-infected hNTCP-HepG2 cells indicated that inactivation of cccDNA was successful. Analysis of likely off-target mutagenesis revealed no unintended sequence changes. Use of ssAAVs to deliver all components required to disable cccDNA by SaCas9 is novel and the technology has curative potential for HBV infection.

Citing Articles

The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption.

Yao Z, Schank M, Zhao J, El Gazzar M, Wang L, Zhang Y Front Genome Ed. 2024; 6:1467449.

PMID: 39444780 PMC: 11496132. DOI: 10.3389/fgeed.2024.1467449.

Making genome editing a success story in Africa.

M Abkallo H, Arbuthnot P, Auer T, Berger D, Burger J, Chakauya E Nat Biotechnol. 2024; 42(4):551-554.

PMID: 38504013 DOI: 10.1038/s41587-024-02187-2.

CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections.

Bartosh U, Dome A, Zhukova N, Karitskaya P, Stepanov G Int J Mol Sci. 2024; 25(1).

PMID: 38203503 PMC: 10779197. DOI: 10.3390/ijms25010334.

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy.

Jacobs R, Dogbey M, Mnyandu N, Neves K, Barth S, Arbuthnot P Microorganisms. 2023; 11(12).

PMID: 38138129 PMC: 10745739. DOI: 10.3390/microorganisms11122985.

CRISPR/Cas9 Landscape: Current State and Future Perspectives.

Tyumentseva M, Tyumentsev A, Akimkin V Int J Mol Sci. 2023; 24(22).

PMID: 38003266 PMC: 10671331. DOI: 10.3390/ijms242216077.

References

Passman M, Weinberg M, Kew M, Arbuthnot P . In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun. 2000; 268(3):728-33. DOI: 10.1006/bbrc.2000.2209. View

Lin S, Yang H, Kuo Y, Liu C, Yang T, Sung K . The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids. 2014; 3:e186. PMC: 4221598. DOI: 10.1038/mtna.2014.38. View

Stanaway J, Flaxman A, Naghavi M, Fitzmaurice C, Vos T, Abubakar I . The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388(10049):1081-1088. PMC: 5100695. DOI: 10.1016/S0140-6736(16)30579-7. View

Tsai S, Zheng Z, Nguyen N, Liebers M, Topkar V, Thapar V . GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2014; 33(2):187-197. PMC: 4320685. DOI: 10.1038/nbt.3117. View

Sunbul M . Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014; 20(18):5427-34. PMC: 4017058. DOI: 10.3748/wjg.v20.i18.5427. View

Hindson C, Chevillet J, Briggs H, Gallichotte E, Ruf I, Hindson B . Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013; 10(10):1003-5. PMC: 4118677. DOI: 10.1038/nmeth.2633. View

Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S . Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2013; 59(5):1726-37. PMC: 4265264. DOI: 10.1002/hep.26982. View

Ely A, Moyo B, Arbuthnot P . Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016; 24(4):671-7. PMC: 4886943. DOI: 10.1038/mt.2016.43. View

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

10.

Brinkman E, Chen T, Amendola M, van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42(22):e168. PMC: 4267669. DOI: 10.1093/nar/gku936. View

11.

Liu X, Hao R, Chen S, Guo D, Chen Y . Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol. 2015; 96(8):2252-2261. DOI: 10.1099/vir.0.000159. View

12.

Wu X, Kriz A, Sharp P . Target specificity of the CRISPR-Cas9 system. Quant Biol. 2015; 2(2):59-70. PMC: 4338555. DOI: 10.1007/s40484-014-0030-x. View

13.

Chamberlain K, Riyad J, Weber T . Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids. Hum Gene Ther Methods. 2016; 27(1):1-12. PMC: 4761816. DOI: 10.1089/hgtb.2015.140. View

14.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

15.

Pliatsika V, Rigoutsos I . "Off-Spotter": very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. Biol Direct. 2015; 10:4. PMC: 4326336. DOI: 10.1186/s13062-015-0035-z. View

16.

Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P . Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2017; 244:311-320. DOI: 10.1016/j.virusres.2017.01.003. View

17.

Seeger C, Sohn J . Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids. 2014; 3:e216. PMC: 4272409. DOI: 10.1038/mtna.2014.68. View

18.

Kennedy E, Bassit L, Mueller H, Kornepati A, Bogerd H, Nie T . Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015; 476:196-205. PMC: 4323668. DOI: 10.1016/j.virol.2014.12.001. View

19.

Nassal M . The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J Virol. 1992; 66(7):4107-16. PMC: 241213. DOI: 10.1128/JVI.66.7.4107-4116.1992. View

20.

Fu Y, Sander J, Reyon D, Cascio V, Joung J . Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014; 32(3):279-284. PMC: 3988262. DOI: 10.1038/nbt.2808. View